COVID-19 Infusion Information for Patients

Updated February 10, 2021

The FDA has issued an Emergency Use Authorization (EUA) for Bamlanivimab and Casirivimab/Imdevimab for treatment of some patients with COVID-19.

The research so far shows that for certain people, taking Bamlanivimab or Casirivimab/Imdevimab may help limit the amount of virus in the body.

This may help your symptoms improve sooner and reduce your need to go into the hospital.
• This is a one-time treatment you receive through an IV.
• The treatment will last about one hour, and we will want you to stay one hour afterward.
• No visitors are allowed in the treatment area. If someone drove you, please have your driver leave contact information so he/she can be called when your treatment is almost
complete.

This treatment is currently very limited. Your provider prescribed this to you because you meet the criteria set forth by the FDA and NMHS, and he or she thinks it will help you recover

If you have any questions, please ask your health care provider.

Locations

Treatments are currently being given in these locations:

NMMC-Tupelo, 612 Brunson Drive, Tupelo
NMMC-Iuka, 1777 Curtis Drive, Iuka
NMMC Gilmore-Amory, 1105 Earl Frye Blvd., Amory
NMMC-West Point, 977 Emergency Dr., West Point
North Mississippi Medical Center-Hamilton, 1256 Military Street South, Hamilton, AL
NMMC-Eupora, 70 Medical Plaza, Eupora

Resources for Patients

Bamlanivimab FDA Fact Sheet for Patients

Casirivimab/Imdevimab FDA Fact Sheet for Patients